Abstract: The invention provides an adhesive sheet for skin, which shows sufficient adhesiveness to the skin and causes low skin irritation. The adhesive sheet contains an adhesive layer formed on a support, in which the adhesive layer contains at least a thermoplastic elastomer, a non-volatile hydrocarbon oil, and polyisobutylene, but no tackifier. The polyisobutylene is a medium molecular weight polyisobutylene with a viscosity average molecular weight of more than 100,000 and not more than 500,000. The invention also provides a percutaneous absorption preparation containing a drug or a pharmaceutically acceptable salt thereof in an adhesive layer of the inventive adhesive sheet for skin.

Abstract: A filter is treated with a reduced amount of a halo active aromatic sulfanomide compound of Formula (I): wherein R1, R2, R3, R4, and R5 are independently selected from hydrogen, COOR?, CON(R?)2, alkoxy, CN, NO2, SO3R?, halogen, substituted or unsubstituted phenyl, sulfonamide, halosulfonamide, and substituted or unsubstituted C1-C12 alkyl; R? is hydrogen, an alkali metal, an alkaline earth metal, substituted C1-C12 alkyl, or unsubstituted C1-C12 alkyl; and R? is hydrogen or substituted or unsubstituted C1-C12 alkyl, where the two R? groups in CON(R?)2 may be independently selected; X is halogen; M is an alkali or alkaline earth metal; and n is the number of water molecules per molecule of the sulfonamide compound. The compound effectively suppresses odors pre-use, in use, and post-use for extended periods of time.

Abstract: Described herein is a silicone replacement for use in a personal care formulation comprising a mixture of at least one polymeric ester and at least one non-polymeric ester. The polymeric ester is an esterification reaction product of (i) at least one first dicarboxylic acid, (ii) at least one first monofunctional alcohol or monofunctional carboxylic acid and (iii) glycerin or derivatives thereof. The non-polymeric ester is an esterification reaction product of (i) at least one second dicarboxylic acid and (ii) at least one second monofunctional alcohol, wherein the replacement is substantially free of silicone. As described is a personal care formulation that is substantially free of silicone, wherein the formulation comprises a silicone replacement consisting substantially of a mixture of at least one polymeric ester as described above, and a non-polymeric ester as described above. Related methods are also described.

Abstract: Methods and compositions are disclosed for delivering lutein or other antioxidant to target tissues such as the eye, in bioactive form, while protecting the antioxidant from degradation. The antioxidant is encapsulated in nanoparticles comprising a protein such as zein or a polymer such as poly(lactic-co-glycolic acid) (PLGA). Preferably a surfactant is associated with the nanoparticles as well, further helping to protect the antioxidant. After the nanoparticles are administered to the target tissue, bioactive antioxidant is released to the tissue over time. Optionally, the nanoparticles are admixed with a thermosensitive, bioadhesive gel to promote slow release of antioxidant. The methods and compositions are useful for treating or preventing conditions such as age-related macular degeneration or cataracts.

Abstract: A process for preparing poly(lactide-co-glycolide) copolymer particles with an average particle size in the range of 50-800 nm includes transferring a mixture of poly(lactide-co-glycolide) copolymer, ethanol and carbon dioxide from a first reactor into a second reactor under rapid reduction of the pressure and expansion with phase separation into a gas phase, an ethanol aerosol and an ethanolic suspension containing poly(lactide-co-glycolide) copolymer particles, removing the carbon dioxide gas and the ethanol aerosol from the second reactor, and obtaining the poly(glycolide-co-lactide) copolymer particles in the form of an ethanolic suspension or in dry form from the second reactor.

Abstract: The present invention concerns pharmaceutical formulations of ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise a solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS. In one aspect, the solid dispersion of ARN-509, a poly(meth)acrylate copolymer and HPMCAS is obtainable, in particular is obtained, by melt-extruding a mixture comprising ARN-509, a poly(meth)acrylate copolymer and HPMCAS and optionally subsequently milling said melt-extruded mixture.

Abstract: The present invention relates to an embolization particle comprising a microparticle coated with a plurality of nanoparticles, which nanoparticles comprise a metal oxide doped with one or more rare earth elements, wherein the metal oxide is titanium dioxide, zinc oxide or cerium dioxide. An embolization particle of the invention for use in the treatment of cancer in combination with X-ray radiation or proton beam radiation, or use in embolization, is also described. The invention also relates to a process for producing an embolization particle comprising a microparticle coated with a plurality of nanoparticles, which nanoparticles comprise a metal oxide doped with one or more rare earth elements, wherein the metal oxide is titanium dioxide, zinc oxide or cerium dioxide, which process comprises: (i) providing a microparticle; (ii) contacting the microparticle with a plurality of the nanoparticles; and (iii) heating the microparticle and the nanoparticles to form the embolization particle.

Abstract: Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.

Abstract: Compositions are provided and described herein which include cosmetic and hair conditioning compositions having a mixture of stearamidopropyl dimethylamine and behenamidopropyl dimethylamine. Also provided are methods for conditioning hair using such mixtures.

Abstract: Organofunctional polyorganosiloxanes, their use in cosmetic compositions, method for treating amino acid based substrates with organofunctional polyorganosiloxanes, compositions comprising the organofunctional polyorganosiloxanes useful for hair straightening and shaping as well as hair coloration and hair color retention.

Abstract: A transdermal cream composition and related method of creating the formulation includes: magnesium chloride, water, hydroxypropyl starch phosphate, at least one of cetearyl olivate and sorbitan olivate, isopropyl palmitate, emulsifying wax, cetyl alcohol, glycerin, Butyrospermum parkii (shea butter). The composition also includes at least one of: iodopropynyl butylcarbamate, phenoxyethanol, caprylyl glycol, benzyl alcohol, benzoic acid, and sorbic acid.

Abstract: The present application relates to an amphiphilic polymer and a method of preparing the same. Furthermore, the present application relates to a micelle including a drug encapsulated by the amphiphilic polymer and a composition including the same. The amphiphilic polymer according to the present application has excellent drug encapsulation properties as well as good dispersion properties in an aqueous solution.

Abstract: A composition including a plurality of particles, wherein the particles include: about 30% to about 95% by weight of a carrier; about 0.1% to about 30% by weight of a perfume; and about 0.00025% to about 30% by weight of a malodor agent; wherein the malodor agent comprises one or more malodor reduction materials having a Blocker Index of less than 3 or a Blocker Index average of 3 to about 0.001; and wherein each of the particles has a mass between about 0.1 mg to about 5 g.

Abstract: Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

Abstract: The present invention relates to the use of the compounds (A) corresponding to formula wherein R1 is hydrogen; a linear or branched C1-C30 aliphatic hydrocarbon residue comprising 0, 1, 2 or 3 double bonds; R2 independently from each other are hydrogen; methyl; ethyl; —OH; —COOR4; —CH2—OH; and —CH2—COOR4; R4 is hydrogen; or a linear or branched C1-C30 aliphatic hydrocarbon residue comprising 0, 1, 2 or 3 double bonds; R3 independently from each other are hydrogen; methyl; ethyl; —OH; —COOR5; —CH2—OH; and —CH2—COOR5; R5 is hydrogen; or a linear or branched C1-C30 aliphatic hydrocarbon residue comprising 0, 1, 2 or 3 double bonds; n is at least 0.

Abstract: The present invention relates to methods and compositions designed for the treatment or management of acute coronary syndromes, particularly, unstable angina and acute myocardial infarction. The methods of the invention comprise the administration of an effective amount of a formulation containing one or more therapeutic agents which specifically decreases or inhibits the activity of phagocytic cells and/or eliminates or diminishes the amount of phagocytic cells including, but not limited to, macrophages and monocytes. The formulations are specifically targeted to phagocytic cells. The invention also provides pharmaceutical compositions of formulations containing one or more therapeutic agents of the invention for administration to subjects currently suffering from or having recently suffered an acute coronary syndrome such as unstable angina and acute myocardial infarction.

Abstract: An esterified cellulose ether comprising aliphatic monovalent acyl groups and groups of the formula —C(O)—R—COOH, R being a divalent hydrocarbon group, has the following properties: i) the degree of neutralization of the groups —C(O)—R—COOH is not more than 0.4, ii) the total degree of ester substitution is from 0.10 to 0.70, and iii) the esterified cellulose ether has a solubility in water of at least 2.0 weight percent at 2 C.

Abstract: A wound management system can comprise a surgically acceptable adhesive disposed over a wound and a surgically acceptable film repositionably disposed over the surgically acceptable adhesive, and methods of managing a wound involving the same.

Abstract: The present invention is directed to particles prepared via the polymerization of at least one surfactant and an isocyanate-containing compound. Pharmaceutical compositions prepared using these particles are also described.

Abstract: Provided are compositions and methods that are useful for personal care compositions. The compositions comprise (a) a cationic polymer comprising polymerized units derived from (i) 30 to 80 weight % of cationic monomers, (ii) 10 to 65 weight % of (meth)acrylamide monomers, and (iii) 0 to 30 weight % of polar non-ionic derivatives of acrylic monomers, and (b) silicone. Also provided are methods of treating hair with such compositions.